Affymax is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions.
The company’s product candidate, Hematide™/peginesatide, has been investigated in Phase 3 trials for the treatment of anemia associated with chronic renal failure.
